| Description | VBY-825 is a reversible inhibitor of cathepsin with high potency against cathepsins B, L, S and V. |
| In vitro | VBY-825是一种有效的（cathepsins）抑制剂，并且其对至少一种（cathepsin），即（cathepsin S），的抑制作用跨越了药理学研究相关的多个物种，特别是小鼠。VBY-825以每日10mg/kg的剂量可在小鼠体内实现超过200nM的稳态血浆浓度，（>200nM），这远高于完全抑制小鼠和人体细胞系中（cathepsins B, F, K, L, S 和 V）的细胞内活性所需的浓度。 |
| molecular weight | 535.55 |
| Molecular formula | C23H29F4N3O5S |
| CAS | 1310340-58-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 125 mg/mL (233.40 mM), Sonication is recommended. |
| References | 1. Elie BT, et al. Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. Biochimie. 2010 Nov;92(11):1618-24. |